Positron emission tomography (PET) in uro-oncology has been one of the slowest areas to develop. There are problems because of the excretion of tracer through the renal tract. Its use in prostate cancer has generally being disappointing, with PET being unable to differentiate malignancy from benign prostatic hypertrophy. In more advanced disease and in the search for the site of recurrence, PET can be of more use. Also, new tracers may prove to be more effective. PET has been shown to be of value in testicular cancer, particularly in defining recurrent disease in residual masses and in patients with raised markers. There is a clear place for PET in some of these cases. Early studies at staging are promising but more work is required to define its exact place. In renal and bladder cancer, PET may be a useful adjunct to conventional imaging in difficult cases and may assist in local staging. In all tumours it is valuable to differentiate fibrosis from recurrent disease in the treatment bed, an area of difficulty for CT/MR.

Author

S F Hain

Contact Details

Corresponding address:
S F Hain
Department of Nuclear Medicine,
Charing Cross Hospital,
Fulham Palace Road,
London W6 8RF,
UK

Reference

ICIS Cancer Imaging Volume 5 Issue 1
DOI: 10.1102/1470-7330.2005.0001

Date Posted

17 January 2005

Print PDF

Size

4.22 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	16 seconds
ADSL 512Kb/s (Broadband):	1 minute 7 seconds
64 Kb/s (ISDN):	9 minutes 0 seconds
33.3 Kb/s (Typical Modem):	17 minutes 18 seconds

Screen PDF

Size

365.47 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	5 seconds
64 Kb/s (ISDN):	45 seconds
33.3 Kb/s (Typical Modem):	1 minute 27 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.